Others have shown that combination inhibition of BRD4 and ATR demonstrates synergistic cytotoxic activity in other cancers such as lymphomas, melanoma and high-grade serous ovarian cancer 58–60, however ARID1A loss as a biomarker of sensitivity was not explored. Here, ARID1A is linked to ovarian serous adenocarcinoma.